OLFM2

Summary

OLFM2 (olfactomedin 2, HGNC:17189) is a protein-coding gene on chromosome 19p13.2, encoding Noelin-2 (O95897). Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation.

Involved in positive regulation of smooth muscle cell differentiation. Acts upstream of or within protein secretion. Located in cytoplasm; extracellular region; and nucleoplasm.

Source: NCBI Gene 93145 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_058164

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17189
Approved symbol	OLFM2
Name	olfactomedin 2
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	OlfC, NOE2
Ensembl gene	ENSG00000105088
Ensembl biotype	protein_coding
OMIM	617492
Entrez	93145

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000264833, ENST00000590410, ENST00000590841, ENST00000592448, ENST00000593091, ENST00000882493, ENST00000923214, ENST00000971550

RefSeq mRNA: 3 — MANE Select: NM_058164 NM_001304347, NM_001304348, NM_058164

CCDS: CCDS12221, CCDS77230, CCDS92509

Canonical transcript exons

ENST00000264833 — 6 exons

Exon	Start	End
ENSE00000674937	9857263	9857482
ENSE00001136208	9853718	9854863
ENSE00001263159	9936304	9936515
ENSE00003480231	9856807	9856913
ENSE00003612836	9857715	9857861
ENSE00003613265	9860645	9860794

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 98.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.8778 / max 364.2967, expressed in 1083 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179051	4.5546	737
179050	1.3302	374
179049	1.2878	383
179045	1.2809	416
179046	0.6219	321
179047	0.6150	257
179044	0.5368	78
179052	0.4446	243
179048	0.2060	113

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.78	gold quality
ganglionic eminence	UBERON:0004023	98.57	gold quality
ventricular zone	UBERON:0003053	98.32	gold quality
anterior cingulate cortex	UBERON:0009835	96.99	gold quality
right frontal lobe	UBERON:0002810	96.57	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.22	gold quality
prefrontal cortex	UBERON:0000451	96.13	gold quality
amygdala	UBERON:0001876	95.50	gold quality
skin of leg	UBERON:0001511	95.40	gold quality
caudate nucleus	UBERON:0001873	94.58	gold quality
nucleus accumbens	UBERON:0001882	94.18	gold quality
hypothalamus	UBERON:0001898	94.10	gold quality
skin of abdomen	UBERON:0001416	94.09	gold quality
putamen	UBERON:0001874	94.01	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.17	gold quality
neocortex	UBERON:0001950	92.22	gold quality
frontal cortex	UBERON:0001870	91.66	gold quality
right adrenal gland cortex	UBERON:0035827	91.50	gold quality
right adrenal gland	UBERON:0001233	91.03	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.01	gold quality
zone of skin	UBERON:0000014	90.79	gold quality
left adrenal gland	UBERON:0001234	90.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.29	gold quality
left adrenal gland cortex	UBERON:0035825	90.18	gold quality
cerebral cortex	UBERON:0000956	89.53	gold quality
forebrain	UBERON:0001890	89.11	gold quality
cerebellar hemisphere	UBERON:0002245	88.84	gold quality
cerebellar cortex	UBERON:0002129	88.66	gold quality
brain	UBERON:0000955	88.05	gold quality
adrenal cortex	UBERON:0001235	87.52	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	23.04
E-MTAB-5061	yes	5.98
E-ANND-3	yes	3.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

49 targeting OLFM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-363-5P	99.46	64.51	1015

Literature-anchored findings (GeneRIF, showing 7)

• The Arg144Gln mutation in OLFM2 is a possible disease-causing mutation in Japanese patients with OAG. Common polymorphisms in OLFM2 and OPTN may interactively contribute to the development of OAG, indicating a polygenic etiology. (PMID:17122126)
• Olfm2 physically interacts with serum response factor (SRF) without affecting the SRF-myocardin interaction. (PMID:25298399)
• Our study indicates that OLFM2 is likely to be important in mammalian eye development and disease and should be considered as a gene for human ocular anomalies. (PMID:27844144)
• plasma OLFM2 is a potential biomarker for restenosis and may be a novel target for the treatment of restenosis. (PMID:29553861)
• New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. (PMID:35806447)
• The Role of Olfactomedin 2 in the Adipose Tissue-Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease. (PMID:36982296)
• OLFM2 promotes epithelial-mesenchymal transition, migration, and invasion in colorectal cancer through the TGF-beta/Smad signaling pathway. (PMID:38350902)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	olfm2a	ENSDARG00000077847
danio_rerio	olfm2b	ENSDARG00000102825
mus_musculus	Olfm2	ENSMUSG00000032172
rattus_norvegicus	Olfm2	ENSRNOG00000020519

Paralogs (9): MYOC (ENSG00000034971), OLFM4 (ENSG00000102837), OLFML3 (ENSG00000116774), OLFM3 (ENSG00000118733), OLFM1 (ENSG00000130558), OLFML2B (ENSG00000162745), OLFML1 (ENSG00000183801), OLFML2A (ENSG00000185585), GLDN (ENSG00000186417)

Protein

Protein identifiers

Noelin-2 — O95897 (reviewed: O95897)

Alternative names: Olfactomedin-2

All UniProt accessions (4): O95897, K7EIS8, K7EKW2, K7ELC6

UniProt curated annotations — full annotation on UniProt →

Function. Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation. TGF-beta induces expression and translocation of OLFM2 to the nucleus where it binds to SRF, causing its dissociation from the transcriptional repressor HEY2/HERP1 and facilitating binding of SRF to target genes. Plays a role in AMPAR complex organization. Is a regulator of vascular smooth-muscle cell (SMC) phenotypic switching, that acts by promoting RUNX2 and inhibiting MYOCD binding to SRF. SMC phenotypic switching is the process through which vascular SMCs undergo transition between a quiescent contractile phenotype and a proliferative synthetic phenotype in response to pathological stimuli. SMC phenotypic plasticity is essential for vascular development and remodeling.

Subunit / interactions. Peripherally associated with AMPAR complex. AMPAR complex consists of an inner core made of 4 pore-forming GluA/GRIA proteins (GRIA1, GRIA2, GRIA3 and GRIA4) and 4 major auxiliary subunits arranged in a twofold symmetry. One of the two pairs of distinct binding sites is occupied either by CNIH2, CNIH3 or CACNG2, CACNG3. The other harbors CACNG2, CACNG3, CACNG4, CACNG8 or GSG1L. This inner core of AMPAR complex is complemented by outer core constituents binding directly to the GluA/GRIA proteins at sites distinct from the interaction sites of the inner core constituents. Outer core constituents include at least PRRT1, PRRT2, CKAMP44/SHISA9, FRRS1L and NRN1. The proteins of the inner and outer core serve as a platform for other, more peripherally associated AMPAR constituents, including OLFM2. Alone or in combination, these auxiliary subunits control the gating and pharmacology of the AMPAR complex and profoundly impact their biogenesis and protein processing. Interacts with GRIA2. Interacts with OLFM1 and OLFM3. Interacts with SRF; the interaction promotes dissociation of SRF from the transcriptional repressor HEY2. Interacts with RUNX2.

Subcellular location. Secreted. Synapse. Membrane. Nucleus. Cytoplasm.

Tissue specificity. Expressed in aortic smooth muscle (at protein level). In the fetus, expressed in the brain and ocular tissues including lens vesicle and optic cup.

Post-translational modifications. N-glycosylated.

Induction. By TGF-beta.

RefSeq proteins (3): NP_001291276, NP_001291277, NP_477512* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003112	Olfac-like_dom	Domain
IPR022082	Noelin_dom	Domain
IPR050605	Olfactomedin-like_domain	Family

Pfam: PF02191, PF12308

UniProt features (17 total): glycosylation site 6, sequence variant 3, mutagenesis site 2, coiled-coil region 2, signal peptide 1, chain 1, disulfide bond 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95897-F1	84.37	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 195–377

Glycosylation sites (6): 441, 74, 155, 275, 310, 399

Mutagenesis-validated functional residues (2):

Position	Phenotype
144	no effect on secretion.
420	completely blocks secretion. also significantly inhibits secretion of olfm1 and olfm3.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 105 (showing top): MYOGENIN_Q6, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, PAX8_B, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_SECRETION, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, MODULE_342, GOCC_PLASMA_MEMBRANE_SIGNALING_RECEPTOR_COMPLEX, GOBP_MUSCLE_CELL_DIFFERENTIATION, GOCC_AMPA_GLUTAMATE_RECEPTOR_COMPLEX, GOCC_SYNAPSE

GO Biological Process (4): signal transduction (GO:0007165), protein secretion (GO:0009306), positive regulation of smooth muscle cell differentiation (GO:0051152), regulation of vascular associated smooth muscle cell dedifferentiation (GO:1905174)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), AMPA glutamate receptor complex (GO:0032281), synapse (GO:0045202), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of cellular process	2
cell communication	1
cellular process	1
signaling	1
cellular response to stimulus	1
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
smooth muscle cell differentiation	1
positive regulation of muscle cell differentiation	1
regulation of smooth muscle cell differentiation	1
regulation of developmental process	1
vascular associated smooth muscle cell dedifferentiation	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
ionotropic glutamate receptor complex	1
cell junction	1

Protein interactions and networks

STRING

890 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OLFM2	AVPR2	P30518	479
OLFM2	OPTN	Q96CV9	476
OLFM2	UBL5	Q9BZL1	446
OLFM2	GRIA1	P42261	437
OLFM2	COL5A3	P25940	417
OLFM2	FBXL12	Q9NXK8	405
OLFM2	TCF23	Q7RTU1	402
OLFM2	PRKCSH	P14314	394
OLFM2	ISYNA1	Q9NPH2	392
OLFM2	SH3BGR	P55822	390
OLFM2	PIDD1	Q9HB75	382
OLFM2	GUK1	Q16774	376
OLFM2	RBMS2	Q15434	371
OLFM2	KRTAP8-1	Q8IUC2	369
OLFM2	OCIAD2	Q56VL3	367

IntAct

80 interactions, top by confidence:

A	B	Type	Score
OLFM1	OLFM2	psi-mi:“MI:0914”(association)	0.640
FBXO6	MAN2B1	psi-mi:“MI:0914”(association)	0.640
SDF2L1	OLFM2	psi-mi:“MI:0914”(association)	0.640
	OLFM2	psi-mi:“MI:0915”(physical association)	0.560
OLFM2		psi-mi:“MI:0915”(physical association)	0.560
OLFM2	NOTCH2NLC	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-3	OLFM2	psi-mi:“MI:0915”(physical association)	0.560
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
ADAMTS4	MANBA	psi-mi:“MI:0914”(association)	0.530
C1orf54	EXTL3	psi-mi:“MI:0914”(association)	0.530
BLOC1S6	OLFM2	psi-mi:“MI:0915”(physical association)	0.370
OLFM2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
OLFM3	AGRN	psi-mi:“MI:0914”(association)	0.350
OLFM1		psi-mi:“MI:0914”(association)	0.350
CGA	TRIO	psi-mi:“MI:0914”(association)	0.350
CXCL5	OLFM2	psi-mi:“MI:0914”(association)	0.350
OLFM3	OLFM2	psi-mi:“MI:0914”(association)	0.350
HLA-G	TMEM131L	psi-mi:“MI:0914”(association)	0.350
BTNL2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
LY86	TMEM131L	psi-mi:“MI:0914”(association)	0.350
IL5RA	POTEF	psi-mi:“MI:0914”(association)	0.350
NCR3	POTEF	psi-mi:“MI:0914”(association)	0.350
DNAJB9	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (117): KRTAP10-3 (Two-hybrid), OLFM2 (Affinity Capture-MS), KRTAP10-3 (Two-hybrid), OLFM2 (Affinity Capture-MS), ZFHX4 (Affinity Capture-MS), RNF40 (Affinity Capture-MS), TUBB1 (Affinity Capture-MS), DVL2 (Affinity Capture-MS), FEM1B (Affinity Capture-MS), OLFM2 (Affinity Capture-MS), KDM5C (Affinity Capture-MS), MSTO1 (Affinity Capture-MS), LRIF1 (Affinity Capture-MS), ZSWIM8 (Affinity Capture-MS), CBY1 (Affinity Capture-MS)

ESM2 similar proteins: A2AV25, A5PJQ2, O35764, O43278, O43827, O70165, O95841, O95897, P02675, P02678, P04115, P12804, P14480, P30203, P33573, Q0P4P2, Q14314, Q1RMR1, Q24K15, Q29041, Q29042, Q29RY7, Q2KJ51, Q2TNK5, Q568Y7, Q5EA66, Q5FB95, Q5I2E5, Q5XK91, Q640P2, Q6AX44, Q6TMA8, Q8BM13, Q8IUK5, Q8K0E8, Q8N539, Q8NI99, Q8R0Z6, Q8R1Q3, Q91ZV7

Diamond homologs: A2BD09, A4IIT5, A6QLD2, B0BNI5, B5MFE9, O70624, O88917, O88923, O88998, O94910, O95490, O95897, O97817, O97827, O97831, P63056, P63057, Q0P3W2, Q0V9V5, Q0VCP3, Q25C36, Q2PT31, Q3UZZ4, Q3V1G4, Q568Y7, Q594P2, Q62609, Q66H86, Q68BL7, Q68BL8, Q6UWY5, Q6UX06, Q80TR1, Q80TS3, Q863A3, Q866N2, Q8BHP7, Q8BK62, Q8BM13, Q8JZZ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	4
Benign	12

Top pathogenic / likely-pathogenic (0)

SpliceAI

1361 predictions. Top by Δscore:

Variant	Effect	Δscore
19:9856803:TCACC:T	donor_loss	1.0000
19:9856804:CA:C	donor_loss	1.0000
19:9856805:AC:A	donor_gain	1.0000
19:9856805:ACCC:A	donor_loss	1.0000
19:9856806:CC:C	donor_gain	1.0000
19:9856909:ACAGC:A	acceptor_gain	1.0000
19:9856910:CAGC:C	acceptor_gain	1.0000
19:9856910:CAGCC:C	acceptor_gain	1.0000
19:9856914:C:CC	acceptor_gain	1.0000
19:9857262:CCCAG:C	donor_gain	1.0000
19:9857266:G:C	donor_gain	1.0000
19:9857710:CCCA:C	donor_loss	1.0000
19:9857712:CA:C	donor_loss	1.0000
19:9857714:C:CG	donor_loss	1.0000
19:9860639:TCTCA:T	donor_loss	1.0000
19:9860640:CTCA:C	donor_loss	1.0000
19:9860643:A:AC	donor_gain	1.0000
19:9860644:C:CC	donor_gain	1.0000
19:9860644:CCTT:C	donor_gain	1.0000
19:9860790:AGAGT:A	acceptor_gain	1.0000
19:9860791:GAGT:G	acceptor_gain	1.0000
19:9860793:GT:G	acceptor_gain	1.0000
19:9860795:C:CC	acceptor_gain	1.0000
19:9869062:ATC:A	donor_gain	1.0000
19:9869064:C:A	donor_gain	1.0000
19:9856800:CACT:C	donor_loss	0.9900
19:9856801:ACTC:A	donor_loss	0.9900
19:9856805:A:AC	donor_gain	0.9900
19:9856806:C:CC	donor_gain	0.9900
19:9856806:CCCGG:C	donor_gain	0.9900

AlphaMissense

2962 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:9854252:G:C	N433K	1.000
19:9854252:G:T	N433K	1.000
19:9854257:A:G	W432R	1.000
19:9854257:A:T	W432R	1.000
19:9854602:A:G	W317R	1.000
19:9854602:A:T	W317R	1.000
19:9856843:C:A	W217C	1.000
19:9856843:C:G	W217C	1.000
19:9856845:A:G	W217R	1.000
19:9856845:A:T	W217R	1.000
19:9856850:C:T	G215D	1.000
19:9856852:G:C	F214L	1.000
19:9856852:G:T	F214L	1.000
19:9856854:A:G	F214L	1.000
19:9854247:C:A	G435V	0.999
19:9854247:C:T	G435D	0.999
19:9854253:T:A	N433I	0.999
19:9854255:C:A	W432C	0.999
19:9854255:C:G	W432C	0.999
19:9854265:A:G	L429P	0.999
19:9854265:A:T	L429H	0.999
19:9854287:A:C	Y422D	0.999
19:9854315:G:C	N412K	0.999
19:9854315:G:T	N412K	0.999
19:9854365:A:C	Y396D	0.999
19:9854410:A:C	Y381D	0.999
19:9854412:A:G	L380P	0.999
19:9854420:G:C	C377W	0.999
19:9854421:C:A	C377F	0.999
19:9854421:C:T	C377Y	0.999

dbSNP variants (sampled 300 via entrez): RS1000022610 (19:9859871 G>A,C), RS1000048748 (19:9913836 G>A,T), RS1000068125 (19:9853803 CTGGGGG>C,CTGGGGGTGGGGG), RS1000069185 (19:9933426 CG>C), RS1000093022 (19:9873464 G>T), RS1000119150 (19:9924575 C>T), RS1000128128 (19:9868154 G>A), RS1000195440 (19:9916529 CA>C), RS1000205352 (19:9897012 C>T), RS1000207431 (19:9906605 A>G), RS1000254798 (19:9907369 C>A,T), RS1000287804 (19:9927509 G>T), RS1000295555 (19:9871784 C>G), RS1000377592 (19:9883646 T>C), RS1000386966 (19:9929562 C>G,T)

Disease associations

OMIM: gene MIM:617492 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST000880_35	Menarche (age at onset)	2.000000e-07
GCST002541_117	Menarche (age at onset)	2.000000e-13
GCST003993_19	Menarche (age at onset)	1.000000e-06
GCST006585_1182	Blood protein levels	6.000000e-157
GCST006914_11	Sleep duration	1.000000e-10
GCST90000025_553	Appendicular lean mass	3.000000e-16

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Benzo(a)pyrene	affects methylation, increases methylation	2
ethyl-p-hydroxybenzoate	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases methylation	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
bisphenol S	increases methylation	1
jinfukang	decreases expression	1
incobotulinumtoxinA	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1
Doxorubicin	increases expression	1
Estradiol	affects cotreatment, increases expression	1
Lipopolysaccharides	affects response to substance, affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	increases expression	1
Aflatoxin B1	increases methylation	1
Asbestos, Serpentine	increases methylation	1
Palmitic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.